Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pathogenic concepts of pulmonary arterial hypertension (PAH).

Published byMyles Gregory Modified over 5 years ago

Similar presentations

Presentation on theme: "Pathogenic concepts of pulmonary arterial hypertension (PAH)."— Presentation transcript:

1 Pathogenic concepts of pulmonary arterial hypertension (PAH).
Pathogenic concepts of pulmonary arterial hypertension (PAH). The major differences and analogous features between cancer and PAH are highlighted. FGF: fibroblast growth factor; PDGF: platelet-derived growth factor; EGF: epidermal growth factor; BMPR2: bone morphogenetic protein receptor 2; ECM: extracellular matrix; ET-1: endothelin-1; 5-HT: serotonin; NO: nitric oxide; PGI2: prostacyclin; Th: T-helper cell; Treg: regulatory T-cell; VEGF: vascular endothelial growth factor. Christophe Guignabert et al. Eur Respir Rev 2013;22: ©2013 by European Respiratory Society

Download ppt "Pathogenic concepts of pulmonary arterial hypertension (PAH)."

Similar presentations

Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 3 Extracellular stimuli to HSC activation

Figure 3 Extracellular stimuli to HSC activation
S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F

S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Platelet-derived growth factor receptors (PDGFRs) and ligand patterns.

Platelet-derived growth factor receptors (PDGFRs) and ligand patterns.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.
Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.
The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.
Timeline of approval of therapies for pulmonary arterial hypertension.

Timeline of approval of therapies for pulmonary arterial hypertension.
Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.
Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.
Stefan Frank, Heiko Kämpfer, Christian Wetzler, Josef Pfeilschifter 

Stefan Frank, Heiko Kämpfer, Christian Wetzler, Josef Pfeilschifter 
Process and mechanisms of blood vessel formation.

Process and mechanisms of blood vessel formation.
Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Similar presentations

Ads by Google